Apophyseal injuries are generally believed to run a self‐limiting course, suggesting conservative treatment is indicated. We summarized the long‐term consequences of lower limb apophyseal injuries after conservative treatment. We conducted a systematic review using the Cochrane methodology, and reported findings according to PRISMA. MEDLINE, EMBASE, Cochrane CENTRAL, PEDro, and SPORTDiscus were searched. Studies had to include participants aged 8‐18 years old, with a clinical diagnosis of apophyseal injury in the lower limb, more specifically Sever's disease, Osgood‐Schlatter disease, or Sinding‐Larsen‐Johansson disease, non‐surgically treated, with a minimum follow‐up time of 1 year, and with at least one of the following outcome measures: pain, secondary structural changes, functional outcome, participation in sports, and recurrent or subsequent injury. PROSPERO registration number: CRD42020146412. Twelve studies on Osgood‐Schlatter disease, three studies on Sever's disease, and no studies on Sinding‐Larsen‐Johansson disease met inclusion criteria. Results of studies varied widely. Important limitations were heterogeneity between studies and lack of high‐quality research studies. Apophyseal injuries do not always appear to be self‐limiting, with some patients experiencing pain, secondary structural changes, a worse functional outcome, and difficulty resuming sports after more than 1 year of follow‐up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.